A Randomized, Single-blinded and Parallel Study to Assess the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia in Healthy Adults
Latest Information Update: 04 Aug 2023
At a glance
- Drugs HS-20090 (Primary) ; Denosumab
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Shanghai Hansoh Biomedical
- 24 Aug 2021 Status changed from not yet recruiting to recruiting.
- 06 Jul 2021 New trial record